GammaCan Files Additional Patent Applications Covering the Treatment of Malignant Melanoma and Colorectal Cancer with the United
January 04 2007 - 6:30AM
Business Wire
GammaCan International Inc.(OTCBB:GCAN), a developer of
immunotherapies for cancer and other diseases, today announced that
the Company filed two Continuations in Part (CIP) with the U.S.
Patent and Trademark Office. The first CIP is titled
�Administration of Gamma Globulins to Treat Metastatic Melanoma�
and builds on the pre-clinical work conducted at GammaCan and
substantiates these findings with data from ongoing clinical
trials. The second CIP is titled �Administration of Gamma Globulins
to Treat Cancer� and provides experimental data supporting the use
of IgG based therapy for colorectal cancers. �These patent filings
further strengthen GammaCan�s intellectual property position for
the use of IgG based therapies to treat cancers in general, and
more specifically, of melanoma and colorectal cancers. Over the
past six months we have made progress with our research and
clinical programs � we now beginning to see the first fruits of
these efforts,� commented Patrick Schnegelsberg CEO. On a Separate
matter GammaCan also announced that the Company extended the
enrollment period for its GCAN 01 phase II trial to enroll
additional patients. About GCAN 01 GCAN 01 is an open label, 30
patient phase II trial designed to evaluate the efficacy and safety
of IgG therapy in late stage cancer patients who failed all current
therapies. The trial is enrolling patients with colon cancer,
melanoma and prostate cancer. The colon and melanoma arms are fully
enrolled. Data from the melanoma arm was presented at a conference
in 2006 and a scientific paper is in press. About GammaCan
International, Inc GammaCan is focusing on the commercialization of
an innovative anti-cancer immunotherapy to treat metastatic cancer.
GammaCan's platform is based on IgG, a safe, relatively non-toxic
human plasma-based product, currently used to treat a variety of
immune deficiencies and autoimmune diseases. IgG works by
strengthening the patient's immune system. Many experts currently
view immunotherapy as a future alternative to today's standard
chemotherapy. GammaCan is developing VitiGam, its second generation
program. VitiGam is an IgG derived from the plasma of vitiligo
donors and is being developed to treat malignant melanoma. GammaCan
owns, and has applied for US patent protection covering the use of
IgG and vitiligo-derived IgG (VitiGam). For more information about
GammaCan visit www.GammaCan.com or call the company's headquarters
in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free
1-866-308-0396 (from North America). Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this
release include statements regarding: the commercialization of an
anti-cancer immunotherapy and the Company developing the boosting
of cancer patients' immune systems with IVIG into an effective
treatment. Actual outcomes and the Company's actual results could
differ materially from those in such forward-looking statements.
Factors that could cause actual results to differ materially
include risks and uncertainties such as the inability to finance
the planned development of the technology, inability to hire
appropriate staff to develop the technology, unforeseen technical
difficulties in developing the technology, inability to obtain
regulatory approval for human use, competitors' therapies proving
more effective, cheaper or otherwise preferable for consumers,
inability to market the product we produce, among other factors,
all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see
the risk factors associated with other early stage medical research
and development companies filed with the SEC on Edgar.
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2023 to Jul 2024